228 related articles for article (PubMed ID: 26566105)
1. Vorapaxar for secondary stroke prevention: perspectives and obstacles.
Serebruany VL; Kim MH; Fortmann SD; Hanley DF
Expert Rev Neurother; 2015; 15(12):1377-82. PubMed ID: 26566105
[TBL] [Abstract][Full Text] [Related]
2. Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial.
Serebruany VL; Kim MH; Hanley DF
Int J Stroke; 2016 Aug; 11(6):614-7. PubMed ID: 26860124
[TBL] [Abstract][Full Text] [Related]
3. Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
Serebruany VL; Kim MH; Golukhova E; Pya Y; Bekbossynova M; Cattaneo M; Marciniak TA
Int J Cardiol; 2016 Jul; 215():273-6. PubMed ID: 27128545
[TBL] [Abstract][Full Text] [Related]
4. Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events.
Frampton JE
Drugs; 2015 May; 75(7):797-808. PubMed ID: 25895464
[TBL] [Abstract][Full Text] [Related]
5. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Arif SA; D'Souza J; Gil M; Gim S
Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
[TBL] [Abstract][Full Text] [Related]
6. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
Lam S; Tran T
Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
[TBL] [Abstract][Full Text] [Related]
8. Vorapaxar in the secondary prevention of atherothrombosis.
Tantry US; Liu F; Chen G; Gurbel PA
Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
[TBL] [Abstract][Full Text] [Related]
9. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
Bhandari B; Mehta B
Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
[TBL] [Abstract][Full Text] [Related]
10. Vorapaxar in atherosclerotic disease management.
Cheng JW; Colucci V; Howard PA; Nappi JM; Spinler SA
Ann Pharmacother; 2015 May; 49(5):599-606. PubMed ID: 25680760
[TBL] [Abstract][Full Text] [Related]
11. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
Whellan DJ; Tricoci P; Chen E; Huang Z; Leibowitz D; Vranckx P; Marhefka GD; Held C; Nicolau JC; Storey RF; Ruzyllo W; Huber K; Sinnaeve P; Weiss AT; Dery JP; Moliterno DJ; Van de Werf F; Aylward PE; White HD; Armstrong PW; Wallentin L; Strony J; Harrington RA; Mahaffey KW
J Am Coll Cardiol; 2014 Mar; 63(11):1048-57. PubMed ID: 24211500
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
Morrow DA; Alberts MJ; Mohr JP; Ameriso SF; Bonaca MP; Goto S; Hankey GJ; Murphy SA; Scirica BM; Braunwald E;
Stroke; 2013 Mar; 44(3):691-8. PubMed ID: 23396280
[TBL] [Abstract][Full Text] [Related]
13. The FDA report on vorapaxar in the elderly: A convoluted dilemma.
Serebruany VL; Fortmann SD
Int J Cardiol; 2015 Dec; 201():601-3. PubMed ID: 26340124
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
Berg DD; Bonaca MP; Braunwald E; Corbalan R; Goto S; Kiss RG; Murphy SA; Scirica BM; Spinar J; Morrow DA
Am J Cardiol; 2016 Apr; 117(7):1055-8. PubMed ID: 26876014
[TBL] [Abstract][Full Text] [Related]
15. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
Scirica BM; Bonaca MP; Braunwald E; De Ferrari GM; Isaza D; Lewis BS; Mehrhof F; Merlini PA; Murphy SA; Sabatine MS; Tendera M; Van de Werf F; Wilcox R; Morrow DA;
Lancet; 2012 Oct; 380(9850):1317-24. PubMed ID: 22932716
[TBL] [Abstract][Full Text] [Related]
16. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA
Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003
[TBL] [Abstract][Full Text] [Related]
17. Vorapaxar in the secondary prevention of atherothrombotic events.
Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
[TBL] [Abstract][Full Text] [Related]
18. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.
Cavender MA; Scirica BM; Bonaca MP; Angiolillo DJ; Dalby AJ; Dellborg M; Morais J; Murphy SA; Ophuis TO; Tendera M; Braunwald E; Morrow DA
Circulation; 2015 Mar; 131(12):1047-53. PubMed ID: 25681464
[TBL] [Abstract][Full Text] [Related]
19. Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.
White HD; Huang Z; Tricoci P; Van de Werf F; Wallentin L; Lokhnygina Y; Moliterno DJ; Aylward PE; Mahaffey KW; Armstrong PW
J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25012288
[TBL] [Abstract][Full Text] [Related]
20. Review of vorapaxar for the prevention of atherothrombotic events.
Wang A
Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
